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Abstract
Background: To determine the expression of bone morphogenetic protein-2 (BMP-2) and its receptors BMPRIA, 
BMPRIB, and BMPRII in epithelial ovarian cancer (EOC) and to analyze their influence on the prognosis of ovarian cancer 
patients.
Methods: Semi-quantitative RT-PCR and western blot were applied to detect the expression of BMP-2 and its receptors 
BMPRIA, BMPRIB, and BMPRII in EOC, benign ovarian tumors, and normal ovarian tissue at the mRNA and protein levels. 
Immunohistochemistry was used to determine the expression of BMP-2 and its receptors in 100 patients with EOC to 
analyze their influence on the five-year survival rate and survival time of ovarian cancer patients.
Results: (1) The mRNA and protein expression levels of BMP-2, BMPRIB, and BMPRII in ovarian cancer tissue were 
remarkably lower than those in benign ovarian tumors and normal ovarian tissue, while no significant differences in 
BMPRIA expression level was found among the three kinds of tissues. (2) The five-year survival rate and the average 
survival time after surgery of EOC patients with positive expression of BMP-2, BMPRIB, and BMPRII were remarkably 
higher than those of patients with negative expression of BMP-2, BMPRIB, and BMPRII. BMPRIA expression was not 
associated with the five-year survival rate or with the average survival time of ovarian cancer patients.
Conclusions: BMP-2, BMPRIB, and BMPRII exhibited low expression in EOC tissue, and variation or loss of expression 
may indicate poor prognosis for ovarian cancer patients.
Background
Ovarian cancer is the most lethal type of malignant
tumors of the female reproductive system, and despite
recent developments in diagnosis and treatment tech-
niques, the five-year survival rate for ovarian cancer
patients is only 20-40%[1]. The low survival rate is likely
due to the lack of early symptoms for this cancer; most
patients are diagnosed at an advanced stage and exhibit
widespread metastasis. At present, the pathological
causes of ovarian cancer are unclear. Thus, it is urgent to
investigate and search for novel treatment regimens.
The development of tumors is believed to be a complex
process involving several genes and several factors, and
more and more influencing factors are emerging. In
recent years, researchers have focused on the correlation
between bone morphogenetic proteins (BMPs) and the
presence of tumors. BMP is a member of the transform-
ing growth factor-β superfamily. Initially, it was thought
to induce bone formation and chondrogenesis in vivo,
and current evidence suggests that it also participates in
various biological processes of cells, such as proliferation,
differentiation, and apoptosis[2]. BMP signaling is medi-
ated by transmembrane serine/threonine kinases,
namely, BMPRI (BMPRIA, BMPRIB) and BMPRII recep-
tors[3]. There are 16 kinds of BMPs, and the majority of
studies have focused on BMP-2, which has been shown to
play a crucial role in the occurrence and development of
breast cancer[4-6], lung cancer[7-11], prostatic carci-
noma[12-14], and colon cancer[15,16]. However, the cor-
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relation between BMP-2 and ovarian cancer remains
unclear. This study was designed to determine the
expression of BMP-2 and its receptors in epithelial ovar-
ian cancer, benign ovarian tumors, and normal ovarian
tissue and to analyze their influence on the five-year sur-
vival rate and average survival time of ovarian cancer
patients.
Methods
Samples
RT-PCR samples: A total of 29 EOC patients, 32 benign
ovarian tumor patients, and 10 patients with normal
ovarian tissue were recruited from Shengjing Hospital,
which is affiliated with China Medical University,
between August 2005 and August 2007.
Western blot samples: A total of 15 EOC patients, 15
benign ovarian tumor patients, and 10 patients with nor-
mal ovarian tissue were recruited from Shengjing Hospi-
tal, which is affiliated with China Medical University,
between August 2005 and August 2007.
Immunohistochemistry samples: One hundred paraf-
fin-embedded specimens of EOC preserved at the
Department of Pathology of Shengjing Hospital between
January 1997 and August 2001 were included in this
study. Specimens were examined for histological grade
based on World Health Organization criteria. All EOC
patients were grade II and grade III. The tumor stages
were determined according to the International Federa-
tion of Gynecology and Obstetrics (FIGO) with surgically
and cytologically stage performed, all EOC patients had
stage III and stage IV. All specimens were fixed with para-
formaldehyde, embedded in paraffin, and prepared as
serial slices of 4 μm in thickness.
All experiment subjects had complete clinical patholog-
ical data and were aged 20-72 years (mean: 50.36 ± 12.30),
and there were no significant differences between age
groups. No patients received radiotherapy, chemother-
apy, biotherapy, or any other operation before surgery for
the cancer. Maximal surgical cytoreduction is followed by
the standard systemic chemotherapy for these patients.
The pathological diagnosis was performed by experts at
the Department of Pathology of Shengjing Hospital and
the Fourth Hospital affiliated with China Medical Univer-
sity. All samples and clinical data were obtained with the
consent from all patients.
Main reagents
BMP-2 rabbit anti-human polyclonal antibody, SABC
immunohistochemical kit, DAB color-developing reagent
(Wuhan Boster, China); β-actin rat anti-human poly-
clonal antibody, BMPRIA rabbit anti-human polyclonal
antibody, BMPRIB rabbit anti-human polyclonal anti-
body, BMPRII goat anti-human polyclonal antibody
(Santa Cruz, USA); BMP-2, BMPRIA, BMPRIB, BMPRII
and internal reference β-actin primers (Shanghai Sangon,
China); Trizol total RNA extraction reagent (Invitrogen,
USA); RT kit and PCR amplification reagents (TaKaRa-
Dalian, China); alkaline phosphatase-labeled goat anti-
rabbit IgG, rabbit anti-goat IgG (Sigma, USA); Bradford
protein kit (Nanjing Keygen, China); nitrocellulose filter
(Shanghai Gene, China), β-naphthyl acid phosphate, O-
dianisidine (tetrazotized; Sigma, USA).
RT-PCR
In accordance with the instructions for the Trizol total
RNA extraction kit, total RNA was extracted from 100
mg specimens, and the ratio of OD260 and OD280 was 1.8-
2.0. The harvested RNA was diluted to a concentration of
1 μg/ul, packaged, and preserved at -70°C. The conditions
for the first round of RT synthesis of cDNA were as fol-
lows: 42°C for 30 min, 99°C for 5 min, and 5°C for 5 min.
PCR reaction conditions were as follows: for BMP-2,
BMPRIA, BMPRII, and β-actin: 94°C for 2 min, 94°C for
30 s, 55°C for 30 s, and 72°C for 45 s for a total of 30
cycles, then 72°C for 7 min; for BMPRIB: 94°C for 2 min,
94°C for 30 s, 53°C for 30 s, and 72°C for 45 s, for a total of
30 cycles, then for 72°C for 7 min. Primer sequences were
as follows:
BMP-2:
5'-CCAACCATGGATTCGTGGTG-3',
5'- GGTACAGCATCGAGATAGCA-3'
BMPRIA:
5'-AATGGAGTAACCTTAGCACCAGAG-3',
5'-AGCTGAGTCCAGGAACCTGTAC-3'
BMPRIB:
5'- GCAGCACAGACGGATATTGT-3',
5'- TTTCATGCCTCATCAACACT-3'
BMPRII:
5'-ACGGGAGAGAAGACGAGCCT-3',
5'-CTAGATCAAGAGAGGGTTCG-3';
β-actin:
5'-GTGGGGCGCCCCAGGCACCA-3',
5'-CTCCTTAATGTCACGCACGATTTC-3'
After 1.5% agarose gel electrophoresis with 1 μg/μl
ethidium bromide dye, RT-PCR products were observed
with a GIS-2020 gel scanning image analytical system. By
using DNA Marker DL2000 as the standard molecular
weight and β-actin as an internal reference, the ratio of
BMP-2, BMPRIA, BMPRIB, BMPRII, and β-actin was
calculated. RT-PCR products were semiquantitatively
analyzed.
Western blot
In accordance with the instructions for the total protein
extraction kit, total protein was extracted from 100 mg
specimens. Protein concentrations were assayed by the
Bradford method, and specimens were adjusted to the
same protein concentration, packaged, and preserved at -Ma et al. Journal of Experimental & Clinical Cancer Research 2010, 29:85
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70°C for later use. With a prestained marker serving as an
index, the necessary gels were selected after polyacrylam-
ide gel electrophoresis was performed, and a nitrocellu-
lose filter was used for the transfer print. The primary
antibody concentration was 1:100 and the secondary
antibody was 1:2,000. By using alkaline phosphatase col-
oration, the protein hybridization band was scanned with
a GIS-2020 digital image analysis system and the absor-
bance value was assayed. The ratios of BMP-2, BMPRIA,
BMPRIB, BMPRII, and β-actin were calculated for the
semiquantitative analysis.
Immunohistochemistry
Paraffin slices were treated according to the SABC immu-
nohistochemical kit, and results were analyzed using a
double-blind method. Five high-power fields (×400) were
selected at random, and two pathologists evaluated
scores independently. PBS, instead of the primary anti-
body, was used as negative control, and specimens were
scored according to the intensity of the dye color and the
number of positive cells. The intensity of the dye color
was graded as 0 (no color), 1 (light yellow), 2 (light
brown), or 3 (brown), and the number of positive cells
was graded as 0 (<5%), 1 (5-25%), 2 (25-50%), 3 (51-75%),
or 4 (>75%). The two grades were added together and
specimens were assigned to one of 4 levels: 0-1 score (-), 2
scores (+), 3-4 scores (++), more than 5 scores (+++). The
positive expression rate was expressed as the percent of
the addition of (++) and (+++) to the total number.
Statistical analysis
Statistical analysis was performed with SPSS version 11.0
software, and P < 0.05 was considered to be statistically
significant. Statistical tests used included the chi square
test and analysis of variance.
Results
RT-PCR
The mRNA expression levels of BMP-2, BMPRIB, and
BMPRII in ovarian cancer tissues was significantly lower
than those in benign ovarian tumors or normal ovarian
tissue. No significant differences in BMPRIA mRNA
expression level were observed among the three kinds of
tissue (Table 1 and Figure 1). The relative content of the
proteins was expressed as mean ± standard deviation
(SD).
Western blot
The relative content of the proteins BMP-2, BMPRIB, and
BMPRII in ovarian cancer tissue was significantly lower
than those in benign ovarian tumors or normal ovarian
tissue. No significant differences in BMPRIA protein
expression level were observed among the three kinds of
tissue (Table 2 and Figure 2). The relative content was
expressed as mean ± standard deviation (SD).
Immunohistochemistry
Positively stained BMP-2 and its receptors BMPRIA,
BMPRIB, and BMPRII were mainly located in the cyto-
plasm of ovarian cancer cells and appeared as light brown
and brown particles (Figure 3).
Retrospective analysis of follow-up visits of patients
showed that the total five-year survival rate of 100
patients was 32% with a mean survival time of 32.42 ±
22.62 months. The five-year survival rate after surgery of
ovarian cancer patients with positive expression of BMP-
2, BMPRIB, and BMPRII was remarkably higher than that
of patients with negative expression of BMP-2, BMPRIB,
and BMPRII. BMPRIA expression was not associated
Figure 1 The mRNA expression of BMP-2 and its receptors detect-
ed by RT-PCR 1: Ovarian cancer tissue; 2: Benign ovarian tumor 
tissue; 3: Normal ovarian tissue; M: Marker.
Table 1: Relative content of mRNA of BMP-2 and its receptors in ovarian tissue
BMP-2 BMPRIA BMPRIB BMPRII
Ovarian cancer 0.875 ± 0.136 1.525 ± 0.158 0.808 ± 0.137 0.834 ± 0.138
Benign ovarian tumor 1.409 ± 0.089 1.569 ± 0.198 1.173 ± 0.143 1.016 ± 0.119
Normal ovarian tissue 1.598 ± 0.082 1.455 ± 0.176 1.234 ± 0.162 1.273 ± 0.179
P value 0.001 0.680 0.001a 0.001
aP = 0.548, comparison between benign ovarian tumor and normal ovarian tissue.Ma et al. Journal of Experimental & Clinical Cancer Research 2010, 29:85
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with the five-year survival rate of ovarian cancer patients
(Table 3).
Discussion
In 1965, Urist successfully induced heterotopic bone for-
mation by grafting decalcified bovine bone into muscles
and skin[17]. Accordingly , we conclude that some sub-
stance in bone matrix is capable of inducing bone forma-
tion, namely BMP. BMP can differentiate mesenchymal
cells into osteoblasts, plays various roles during embry-
onic development, and is of crucial importance to the
nervous system, hematopoietic cells, the heart and liver,
etc. BMP cannot act without its receptors, namely,
BMPRI (BMPRIA and BMPRIB) and BMPRII, which are
located on chromosomes 10q23, 4q22-24, and 2q33-34.
BMPRIA mediates growth stimulation signals, and
BMPRIB transfers growth inhibition signals[3]. BMPs
bind with type II receptors first, after which the type II
receptor phosphorylates the type I receptor. The recep-
tor-ligand complex phosphorylates the Smad system, and
then the complex shifts into the cell nucleus and is
involved in gene transcription, thus transferring the BMP
signal to the target gene.
At present, there are 16 known BMPs, and the majority
of research has focused on BMP-2. In 1988, Wozney
screened a gene named hBMP-2 from human U-20S cell
cDNA based on a bovine BMP amino acid sequence[18].
The hBMP-2 cDNA was 1188 bp in length, encoded 396
amino acids, and was located on chromosome 20 in the
p21 region.
BMP-2 plays an important physiological role in various
tissues throughout the body and has been shown to be
expressed in tumor tissues. Moreover, its effects vary
depending on the tissue. For example, studies have dem-
onstrated that BMP-2 and its receptors are expressed in
breast cancer[19], colon cancer[15], gastric cancer[20]
and that its expression may be associated with the biolog-
ical behavior of the tumor. In vitro trials have confirmed
that BMP-2 can inhibit the growth of some tumors. Con-
versely, other research has suggested that BMP-2 can
stimulate the growth of tumor cells in vitro, such as lung
cancer[9,10] and prostatic carcinoma[21]. There are only
a few reports on the correlation of BMP-2 and ovarian
cancer. For instance, Kiyozuka [22] and Le Page [23] both
detected the expression of BMP-2 in ovarian cancer tis-
sues, and Kiyozuka further confirmed that BMP-2 was
involved in the formation of serous ovarian cancer psam-
moma bodies. Soda[16] has reported that BMP-2 can
inhibit the growth of cancer cell clones in 2 of 15 ovarian
cancer patients, but no study has investigated the influ-
ence of BMP-2 on prognosis for ovarian cancer patients
or the underlying mechanisms behind its role in the
development of ovarian cancer.
In this study, BMP-2 was shown to be expressed in
ovarian cancer, benign ovarian tumors, and normal ovar-
ian tissue, and its expression in ovarian cancer was clearly
lower than the latter two. This evidence suggests that the
BMP-2 gene is likely expressed in normal ovarian tissue,
where it acts as a protective factor. Thus, variation or loss
of its expression may promote the development of ovar-
ian cancer. The BMP-2 receptors BMPRIA, BMPRIB, and
BMPRII were also expressed in all three types of tissue,
and the expression levels of BMPRIB and BMPRII in
ovarian cancer tissue was significantly lower than those
in benign ovarian tumors and normal ovarian tissue,
although the difference in the BMPRIA expression level
between the different tissues was not significant. This
suggests that BMP-2 may act through its receptors,
BMPRIB and BMPRII, in ovarian cancer. Previous studies
have shown that BMPRIA mediates growth stimulation
signals, while BMPRIB transfers growth inhibition sig-
nals. Our evidence suggests that the weakening of the
Figure 2 The protein expression of BMP-2 and its receptors de-
tected by western blot 1: Ovarian cancer tissue; 2: Benign ovarian 
tumor tissue; 3: Normal ovarian tissue.
Table 2: Relative content of BMP-2 protein of BMP-2 and its receptors in ovarian tissues
BMP-2 BMPRIA BMPRIB BMPRII
Ovarian cancer 0.805 ± 0.105 0.951 ± 0.101 0.816 ± 0.108 0.867 ± 0.119
Benign ovarian tumor 0.958 ± 0.103 0.911 ± 0.113 0.905 ± 0.115 0.974 ± 0.097
Normal ovarian tissue 0.975 ± 0.082 1.026 ± 0.099 1.029 ± 0.087 1.077 ± 0.103
P value 0.019 0.361 0.042 0.043Ma et al. Journal of Experimental & Clinical Cancer Research 2010, 29:85
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inhibitory effect of BMP-2 and BMPRIB may promote the
development of ovarian cancer. It is possible that
BMPRIA has no correlation with the development of
ovarian cancer. That is, the development of ovarian can-
cer is not due to the stimulatory effect of BMPRIA.
In order to investigate the influence of BMP-2 on the
prognosis of ovarian cancer patients, 100 patients were
followed up after their surgery. Their five-year survival
rate was 32%, a rate that is consistent with other pub-
lished reports. Immunohistochemistry results demon-
strated that ovarian cancer patients with positive
expression of BMP-2, BMPRIB, and BMPRII exhibited
remarkably higher five-year survival rates and average
survival rates than patients with negative expression of
BMP-2, BMPRIB, and BMPRII. BMPRIA showed no
association with five-year survival rate or with survival
time of ovarian cancer patients. BMP-2, BMPRIB, and
BMPRII may play a part in the occurrence and develop-
ment of ovarian cancer, and the variation or loss of
expression of BMP-2, BMPRIB, and BMPRII may be an
indicator of poor prognosis for ovarian cancer patients.
Further studies conducted with larger sample sizes are
needed to confirm this association.
Our study suggests that BMP-2 and its receptors
BMPRIB and BMPRII are likely to be involved in the
development of ovarian cancer, and attenuation or loss of
expression may result in or indicate poor prognosis for
ovarian cancer patients. However, the specific pathway
and mechanisms driving this effect need further study, if
novel treatments for ovarian cancer are to be achieved
through better understanding of its pathogenesis.
Conclusions
BMP-2, BMPRIB, and BMPRII exhibited a low expression
in EOC tissue. The variation or loss of expression of these
markers may indicate poor prognosis for ovarian cancer
patients.
Abbreviation list
EOC: epithelial ovarian cancer; BMPs: bone morphoge-
netic proteins; BMP-2: bone morphogenetic protein-2;
BMPRIA: bone morphogenetic protein-2 receptor IA;
BMPRIB: bone morphogenetic protein-2 receptor IB;
BMPRII: bone morphogenetic protein-2 receptor II.
Competing interests
The authors declare that they have no competing interests.
Authors' contributions
YM carried out RT-PCR and Western blot, performed the statistical analysis and
wrote the paper. LM participated in the design of the study and contributed
with drafting the manuscript. QG carried out the immunohistochemistry stud-
ies. SLZ participated in coordination. All authors read and approved the final
manuscript.
Acknowledgements
This study was supported by China National Nature Science Fund 
(No.30100104) to Dr. Lin Ma.
Author Details
Department of Obstetrics and Gynecology, Shengjing Hospital of China 
Medical University, Shenyang 110004, China
Figure 3 Expression of BMP-2, BMPRIA, BMPRIB, and BMPRII in 
epithelial serous ovarian cancer detected by immunohistochem-
istry (×400) A: BMP-2, B: BMPRIA, C: BMPRIB, D: BMPRII.
Table 3: Correlation of the expression of BMP-2 and its receptors with survival rate and survival time of ovarian cancer 
patients
BMP2 BMPRIA BMPRIB BMPRII
Positive expression rate (%) 62 49 62 53
Negative expression rate (%) 38 51 38 47
Five-year survival rate of positive cases 40.32 32.66 41.94 41.51
Five-year survival rate of negative cases 18.42 31.37 15.79 21.28
P value 0.023 0.891 0.007 0.030
Survival time of negative cases 37.27 ± 21.46 33.71 ± 21.95 37.66 ± 22.54 37.21 ± 22.10
Survival time of negative cases 24.50 ± 22.47 31.18 ± 23.40 23.87 ± 20.25 27.02 ± 22.20
P value 0.006 0.577 0.003 0.024Ma et al. Journal of Experimental & Clinical Cancer Research 2010, 29:85
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